Properly stored medication ensures that any genetic advantage or sensitivity is not masked by degraded compound potency
Representative Michele Reneau voiced strong opposition, warning the state could face unintended consequences
Realistic Long-Term Results and Maintenance Clinical data from SURMOUNT trials shows that sustained weight loss on tirzepatide continues through 72 weeks of treatment, with most patients losing 20-22% of their starting body weight
Notably, this cohort exhibited a more dysfunctional metabolic profile, with prevalence rates of obesity, type 2 diabetes mellitus (T2DM), metabolic syndrome, dyslipidemia, and hypertension of 43%, 25%, 52%, 92%, and 32%, respectively
Oklahoma City residents receive clear, dependable guidance
The results could also unlock a potentially massive market for tirzepatide if it is approved as an option for overweight people with pre-diabetes